MX340533B - Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. - Google Patents

Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.

Info

Publication number
MX340533B
MX340533B MX2013015078A MX2013015078A MX340533B MX 340533 B MX340533 B MX 340533B MX 2013015078 A MX2013015078 A MX 2013015078A MX 2013015078 A MX2013015078 A MX 2013015078A MX 340533 B MX340533 B MX 340533B
Authority
MX
Mexico
Prior art keywords
bacterial infections
octan
diazabicyclo
derivatives
treatment
Prior art date
Application number
MX2013015078A
Other languages
English (en)
Other versions
MX2013015078A (es
Inventor
Keshav Deshpande Prasad
Bhawasar Satish
Bhagwat Sachin
Jagdishwar Patil Vijaykumar
Tadiparthi Ravikumar
Sampatrao Pawar Shivaji
Bhaginath Jadhav Sunil
Vitthalrao Deshmukh Vikas
Kisan Dabhade Sanjay
Dond Bharat
Birajdar Satish
Usman Shaikh Mohammad
Dekhane Deepak
Ambalal Patel Piyush
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015078A publication Critical patent/MX2013015078A/es
Publication of MX340533B publication Critical patent/MX340533B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R43/00—Apparatus or processes specially adapted for manufacturing, assembling, maintaining, or repairing of line connectors or current collectors or for joining electric conductors
    • H01R43/04—Apparatus or processes specially adapted for manufacturing, assembling, maintaining, or repairing of line connectors or current collectors or for joining electric conductors for forming connections by deformation, e.g. crimping tool
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R43/00—Apparatus or processes specially adapted for manufacturing, assembling, maintaining, or repairing of line connectors or current collectors or for joining electric conductors
    • H01R43/04—Apparatus or processes specially adapted for manufacturing, assembling, maintaining, or repairing of line connectors or current collectors or for joining electric conductors for forming connections by deformation, e.g. crimping tool
    • H01R43/048—Crimping apparatus or processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/51—Plural diverse manufacturing apparatus including means for metal shaping or assembling
    • Y10T29/5102—Binding or covering and cutting
    • Y10T29/5103—Cutting covering material only
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/51—Plural diverse manufacturing apparatus including means for metal shaping or assembling
    • Y10T29/5136—Separate tool stations for selective or successive operation on work
    • Y10T29/5137—Separate tool stations for selective or successive operation on work including assembling or disassembling station
    • Y10T29/5142—Separate tool stations for selective or successive operation on work including assembling or disassembling station and means to sever work from supply
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/53—Means to assemble or disassemble
    • Y10T29/5313—Means to assemble electrical device
    • Y10T29/532—Conductor
    • Y10T29/53209—Terminal or connector
    • Y10T29/53213—Assembled to wire-type conductor
    • Y10T29/53235—Means to fasten by deformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I): (ver Fórmula) su preparación y su uso en la prevención o el tratamiento de infecciones bacterianas.
MX2013015078A 2011-08-30 2012-08-24 Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. MX340533B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2424MU2011 2011-08-30
PCT/IB2012/054296 WO2013030735A1 (en) 2011-08-30 2012-08-24 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
MX2013015078A MX2013015078A (es) 2014-02-11
MX340533B true MX340533B (es) 2016-07-13

Family

ID=74872459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015078A MX340533B (es) 2011-08-30 2012-08-24 Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.

Country Status (14)

Country Link
US (3) US9006230B2 (es)
EP (1) EP2872510B1 (es)
JP (1) JP5677634B2 (es)
KR (1) KR101618424B1 (es)
CN (1) CN103649088B (es)
AU (1) AU2012303693B2 (es)
BR (1) BR112013032974A2 (es)
CA (1) CA2845108C (es)
ES (1) ES2606059T3 (es)
MX (1) MX340533B (es)
PT (1) PT2872510T (es)
RU (1) RU2570423C2 (es)
WO (1) WO2013030735A1 (es)
ZA (1) ZA201307963B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2014011827A (es) * 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
US9120795B2 (en) * 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
JP2016532711A (ja) 2013-09-06 2016-10-20 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ757221A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015110966A1 (en) * 2014-01-21 2015-07-30 Wockhardt Limited 7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents
CN106132969A (zh) * 2014-02-14 2016-11-16 森普拉制药公司 用于治疗糖尿病和肝病的组合物和方法
WO2015150891A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester
WO2015150890A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester
BR112016024235A2 (pt) * 2014-04-18 2017-08-15 Wockhardt Ltd composições farmacêuticas compreendendo agentes antibacterianos
WO2015173665A1 (en) * 2014-05-14 2015-11-19 Wockhardt Limited A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
MX2017011611A (es) * 2015-03-10 2018-03-23 Aurigene Discovery Tech Ltd Compuestos de tiadiazol y 1,3,4-oxadiazol 3-sustituidos como inmunomoduladores.
WO2016157057A1 (en) * 2015-03-27 2016-10-06 Wockhardt Limited A process for preparation of sodium salt of (2s, 5r) sulfuric acid mono-(2-[1,3,4]oxadiazol-2-yl-7-oxo-1,6-diazabicyclo[3.2.1 ]oct-6-yl)ester
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US10570131B2 (en) * 2015-03-31 2020-02-25 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3281942A4 (en) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
CN108137567A (zh) 2015-10-02 2018-06-08 乐高化学生物科学股份有限公司 用于抑制β-内酰胺酶的组合物和方法
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
EP3184529A1 (en) * 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017190043A1 (en) * 2016-04-29 2017-11-02 University Of Kansas Cephalosporin-type compounds
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN110709081B (zh) * 2017-05-08 2023-09-22 恩塔西斯治疗公司 用于治疗细菌感染的化合物及方法
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
CN109400607B (zh) * 2017-08-16 2021-11-05 江苏奥赛康药业有限公司 阿维巴坦中间体及其制备方法
EP3719020B1 (en) 2017-12-01 2022-09-21 Qilu Pharmaceutical Co., Ltd. Crystal form of beta-lactamase inhibitor and preparation method therefor
US20200325139A1 (en) * 2017-12-22 2020-10-15 Assistance Publique-Hopitaux De Paris New antibiotics targeting mycobacteria
EP3728259A1 (en) * 2017-12-22 2020-10-28 Centre National de la Recherche Scientifique New beta-lactamase inhibitors targeting gram negative bacteria
EP3744722A4 (en) 2018-01-25 2021-11-03 Suzhou Sinovent Pharmaceuticals Co., Ltd. Ss-LACTAMASE INHIBITOR AND ITS USE
EP3833665B1 (en) * 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN118215665A (zh) 2021-11-17 2024-06-18 苏州信诺维医药科技股份有限公司 β-内酰胺酶抑制剂中间体及制备方法
CN116023379A (zh) * 2022-12-07 2023-04-28 江西国药有限责任公司 一种阿维巴坦钠及其制备方法
CN121021508A (zh) * 2025-10-29 2025-11-28 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10008A (en) * 1853-09-13 India-rtjbbee
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.

Also Published As

Publication number Publication date
CN103649088B (zh) 2016-05-11
RU2014107902A (ru) 2015-10-10
CA2845108C (en) 2015-06-16
CN103649088A (zh) 2014-03-19
US20140088068A1 (en) 2014-03-27
ZA201307963B (en) 2015-01-28
US20140288064A1 (en) 2014-09-25
KR101618424B1 (ko) 2016-05-04
BR112013032974A2 (pt) 2016-09-06
CA2845108A1 (en) 2013-03-07
NZ616959A (en) 2015-01-30
US20150336957A1 (en) 2015-11-26
WO2013030735A1 (en) 2013-03-07
MX2013015078A (es) 2014-02-11
RU2570423C2 (ru) 2015-12-10
EP2872510A1 (en) 2015-05-20
AU2012303693A1 (en) 2013-11-07
US9499544B2 (en) 2016-11-22
JP5677634B2 (ja) 2015-02-25
JP2014525434A (ja) 2014-09-29
ES2606059T3 (es) 2017-03-17
US9127004B2 (en) 2015-09-08
PT2872510T (pt) 2017-03-01
EP2872510B1 (en) 2016-11-23
US9006230B2 (en) 2015-04-14
AU2012303693B2 (en) 2014-07-03
KR20140025526A (ko) 2014-03-04

Similar Documents

Publication Publication Date Title
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
IN2012DN01269A (es)
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
NZ593111A (en) Antibacterial compounds
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015501088A1 (en) Dimeric compounds
HK1201836A1 (en) Novel pyrrole derivatives
MX340574B (es) Imidazo pirazinas.
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX342947B (es) Tratamiento de diabetes tipo 2.
SG10201900541QA (en) Derivatives of xanthone compounds
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
PH12015500399A1 (en) Azaindolines
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
IN2013MU03216A (es)
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.

Legal Events

Date Code Title Description
FG Grant or registration